

## **Product** Data Sheet

# Liothyronine sodium hydrate

**Cat. No.:** HY-A0070B **CAS No.:** 345957-19-9

Molecular Formula: C<sub>15</sub>H<sub>12</sub>I<sub>3</sub>NO<sub>4</sub>.xH<sub>2</sub>O.Na

Target: Endogenous Metabolite; Thyroid Hormone Receptor

Pathway: Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

$$HO$$
 $ONE$ 
 $NH_2$ 
 $NH_2O$ 

### **BIOLOGICAL ACTIVITY**

Description	Liothyronine sodium hydrate is an active form of thyroid hormone. Liothyronine sodium hydrate is a potent thyroid hormone receptors TR $\alpha$ and TR $\beta$ agonist with K <sub>i</sub> s of 2.33 nM for hTR $\alpha$ and hTR $\beta$ , respectively [1][2][3].
IC <sub>50</sub> & Target	Human Endogenous Metabolite
In Vitro	Liothyronine (T3, 100 nM) sodium hydrate stimulates the proliferation of hepatocarcinema cells in which TR $\beta$ 1 is overexpressed <sup>[1]</sup> . Liothyronine sodium hydrate binds to human $\beta$ 1 thyroid hormone receptor (hTR $\beta$ 1), and changes its conformation. Liothyronine sodium hydrate promotes growth, induces differentiation and regualtes metabolic effects <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **CUSTOMER VALIDATION**

- Cell Metab. 2023 Sep 7;S1550-4131(23)00304-2.
- Nat Commun. 2023 Jun 2;14(1):3208.
- JCI Insight. 2021 Jun 22;6(12):142838.
- J Med Chem. 2022 Jan 21.
- Food Science and Human Wellness. 2023 Nov;12(6);2061-2072.

See more customer validations on www.MedChemExpress.com

#### **REFERENCES**

- [1]. Lin KH, et al. Stimulation of proliferation by 3,3',5-triiodo-L-thyronine in poorly differentiated human hepatocarcinoma cells overexpressing beta 1 thyroid hormone receptor. Cancer Lett. 1994 Oct 14;85(2):189-94.
- [2]. Bhat MK, et al. Conformational changes of human beta 1 thyroid hormone receptor induced by binding of 3,3',5-triiodo-L-thyronine. Biochem Biophys Res Commun. 1993 Aug 31;195(1):385-92.
- [3]. Hiroaki Shiohara, et al. Discovery of novel indane derivatives as liver-selective thyroid hormone receptor  $\beta$  (TR $\beta$ ) agonists for the treatment of dyslipidemia. Bioorg Med

Chem. 2012 Jun 1;20(11):3622-34.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com